ERBB2 and breast carcinoma: Well known since decades as an adverse prognostic factor, the more recent insight that breast cancers expressing HER2/neu are more susceptible to anthracycline-based chemotherapy (Pritchard et al, 2006) as well as the introduction of the HER2/neu antibody trastuzumab into the adjuvant setting has had significant impact on the prognosis of this particular subgroup of breast cancer patients (Slamon et al, 2001).